Navigation Links
NeurogesX CEO Anthony DiTonno to Retire by Year End
Date:4/29/2011

SAN MATEO, Calif., April 29, 2011 /PRNewswire/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that long time CEO Anthony DiTonno will retire by December 31, 2011. The Board of Directors has initiated a formal executive search for a Chief Executive Officer.

Anthony DiTonno commented, "I have been CEO of NeurogesX for more than eight years and we have accomplished the objectives I established for myself when I joined the Company in March 2003. It has been my privilege to work with my colleagues at NeurogesX to take Qutenza through all phases of clinical development and regulatory approvals throughout the world resulting in the successful launch of Qutenza in the United States by our sales team and with our partner Astellas in Europe, the Middle East and Africa. Our focus on finding a replacement will be to find someone with the appropriate commercial and business experience to take the Company to the next level. As we enter our second full year of commercialization, the timing is ideal for this transition to lead this great company into the future. Decisions like this are difficult and I cannot overstate my enthusiasm for Qutenza and NeurogesX going forward."

Jean-Jacques Bienaime commented, "The Board of Directors thanks Tony for his vision, leadership and tenacity during his tenure as CEO. We are pleased that he has agreed to continue to lead the Company up to the end of the year to assure a smooth transition of leadership."

Mr. Bienaime continued, "At the same time, we are excited to have Gary Lyons join our board. Gary has extensive biotech experience and demonstrated success in commercial, business development and financing, which I believe will benefit the Company greatly."

Gary A. Lyons served as a director of Neurocrine Biosciences since Febru
'/>"/>

SOURCE NeurogesX
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX to Pursue Expanded U.S. Label for Qutenza® (capsaicin) 8% Patch in HIV-Associated Neuropathy
2. NeurogesX to Present at J.P. Morgan Health Care Conference
3. NeurogesX to Present at Piper Jaffray Health Care Conference
4. NeurogesX Reports Third Quarter 2009 Results
5. NeurogesX to Present at Two November Conferences
6. NeurogesX to Present at UBS Global Life Sciences Conference
7. NeurogesX to Present at Upcoming Fall Conferences
8. NeurogesX Appoints New Board Director and Audit Committee Chairman
9. NeurogesX Reports Second Quarter 2009 Results
10. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
11. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Selexis SA, a serial innovation ... Banks (RCBs) used for drug discovery to commercial manufacturing, ... include Next-Generation Sequencing (NGS) data packages. The ... manufacturing by ensuring the integrity of the gene, validation ...
(Date:1/22/2015)... Jersey , 22 de enero de 2015  El Dr. ... hoy su llamada a nominaciones para 2015. Este prestigioso ... hecho, o tiene el potencial para hacer, contribuciones destacadas ... se aceptarán hasta el 15 de marzo de 2015 ...
(Date:1/22/2015)... Jan. 22. 2015  Varian Medical Systems (NYSE: VAR ... honored for its commitment to sustainability with inclusion on a ... the highest ranked healthcare equipment company among the Corporate Knights ... World Economic Forum at Davos, Switzerland . ...
(Date:1/22/2015)... , Jan. 22, 2015  Derma Sciences, Inc. (Nasdaq: ... focused on advanced wound care, announces that AMNIOEXCEL® ... have been added to the Premier, Inc. Regenerative ... opportunity for the AMNIOEXCEL® and AMNIOMATRIX® product lines, ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... often experience a difficult time in securing conventional loans ... high-technology firms in located in the Eau Claire region ... some creative regional business collaboration. A group of nine ... Claire County have come together to create a $1 ...
... MADISON, Wis. - The Wisconsin Alumni Research Foundation ... Mentor Corporation a California-based publicly traded company (NYSE: MNT), ... marketing rights to the proprietary botulinum toxin technology developed ... pay WARF a royalty on sales of Botulinum toxin ...
... the passage of the much-hailed (and cursed) Sarbanes-Oxley ... have restructured their boards, revised their financial recording ... ethics. Many people have asked whether privately ... the same requirements now imposed upon public companies. ...
Cached Biology Technology:Eau Claire Pulls Together, Forms Million-Dollar Technology Loan Program 2Mentor Licenses Botulinum From WARF and Plans Wisconsin Manufacturing Facility 2Sarbanes-Oxley for the Rest of Us 2Sarbanes-Oxley for the Rest of Us 3Sarbanes-Oxley for the Rest of Us 4
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ... in general the State of Washington,s ... a new enrollment and central issuance system for driver,s licenses ... The project planning and development will start in January ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
(Date:1/22/2015)... Issued by Small Cap IR. In 2011, Nilson Report,s annual ... merchants on the leading payment cards rose to $135.3 billion ... prepaid cards reached 6.54 billion.  Eight million credit card users ... 2012, and credit and debit card fraud resulted in $11.27 ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... Philadelphia, PA, April 30, 2012 It is often ... eating habits, as they try to set a good example ... the addition of children into the home may affect parents, ... juggling schedules, or a child,s eating preferences may influence how ...
... can cause obesity, the fear of not having enough food ... to be presented Saturday, April 28, at the Pediatric Academic ... about not having enough food to feed one,s family, a ... families often are overweight, too. "Understanding the reasons why ...
... A water-rich polka dot pattern takes over the traditional rectangular ... years of Landsat images. In the dry Texas panhandle near ... irrigation, a farming method that improves water distribution to fields. ... Center-pivot irrigation works by pumping water from the center of ...
Cached Biology News:Starting a family does not encourage parents to eat healthier 2Fear of not having enough food may lead to obesity 2NASA's Landsat satellites see Texas crop circles 2
... of 3 siRNAs specifically targeted to your ... product. The siTrio reagent guarantees you get ... gene when used under standard conditions (100 ... optimal transfection with one of B-Bridges controls). ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
... has improved stability and convenience from the former ... has overcome this problem but also produced some ... the formulation of HRP conjugated antibody from lyophilized ... change, the stability of the conjugate has improved ...
... multi-purpose, high gel-strength agarose suitable for a ... conventional constant field to Pulsed Field Gel ... strength and exclusion limits, Multi ABgarose can ... running times. This in turn means reduced ...
Biology Products: